Charles Schwab
PHAT icon

Charles Schwab’s Phathom Pharmaceuticals PHAT Stock Holding History

Charles Schwab’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.55M Buy
419,094
+10,079
+2% +$115K ﹤0.01% 2522
2026
Q1 		$4.54M Buy
409,015
+11,105
+3% +$140K ﹤0.01% 2448
2025
Q4 		$6.6M Buy
397,910
+32,006
+9% +$457K ﹤0.01% 2323
2025
Q3 		$4.31M Buy
365,904
+5,744
+2% +$59.3K ﹤0.01% 2503
2025
Q2 		$3.45M Buy
360,160
+12,125
+3% +$67.1K ﹤0.01% 2490
2025
Q1 		$2.18M Sell
348,035
-5,003
-1% -$30.4K ﹤0.01% 2585
2024
Q4 		$2.87M Buy
353,038
+60,178
+21% +$745K ﹤0.01% 2563
2024
Q3 		$5.29M Buy
292,860
+6,990
+2% +$97.7K ﹤0.01% 2349
2024
Q2 		$2.94M Buy
285,870
+21,376
+8% +$220K ﹤0.01% 2572
2024
Q1 		$2.81M Buy
264,494
+1,970
+0.8% +$16.7K ﹤0.01% 2493
2023
Q4 		$2.4M Buy
262,524
+15,843
+6% +$137K ﹤0.01% 2557
2023
Q3 		$2.56M Buy
246,681
+67,811
+38% +$930K ﹤0.01% 2525
2023
Q2 		$2.56M Buy
178,870
+7,263
+4% +$83.7K ﹤0.01% 2475
2023
Q1 		$1.23M Sell
171,607
-1,647
-1% -$14.5K ﹤0.01% 2673
2022
Q4 		$1.94M Buy
173,254
+16,574
+11% +$171K ﹤0.01% 2580
2022
Q3 		$1.74M Buy
156,680
+36,866
+31% +$351K ﹤0.01% 2620
2022
Q2 		$1.01M Sell
119,814
-6,373
-5% -$65.5K ﹤0.01% 2795
2022
Q1 		$1.72M Buy
126,187
+2,888
+2% +$46.7K ﹤0.01% 2700
2021
Q4 		$2.43M Buy
123,299
+2,428
+2% +$57.1K ﹤0.01% 2637
2021
Q3 		$3.88M Buy
120,871
+13,751
+13% +$457K ﹤0.01% 2485
2021
Q2 		$3.63M Buy
107,120
+19,864
+23% +$711K ﹤0.01% 2505
2021
Q1 		$3.28M Buy
87,256
+11,358
+15% +$475K ﹤0.01% 2495
2020
Q4 		$2.52M Buy
75,898
+111
+0.1% +$4.5K ﹤0.01% 2533
2020
Q3 		$2.78M Sell
75,787
-5,881
-7% -$204K ﹤0.01% 2372
2020
Q2 		$2.69M Buy
81,668
+13,065
+19% +$502K ﹤0.01% 2312
2020
Q1 		$1.77M Buy
68,603
+816
+1% +$27.3K ﹤0.01% 2316
2019
Q4 		$2.11M Buy
+67,787
New +$1.7M ﹤0.01% 2401

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Charles Schwab's PHAT Position: Q2 2026 in Review

Charles Schwab increased its Phathom Pharmaceuticals (PHAT) stake by 2.5% in Q2 2026, buying an estimated $115K and bringing the position to 419,094 shares worth $4.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2522.

Charles Schwab first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $6.6M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Charles Schwab held 419,094 shares of Phathom Pharmaceuticals worth $4.55M as of Q2 2026.
  • Charles Schwab bought 10,079 Phathom Pharmaceuticals shares in Q2 2026, an estimated $115K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2522 holding.
  • Charles Schwab first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Charles Schwab's Phathom Pharmaceuticals position peaked at $6.6M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.